We've compiled a collection of scientific publications relevant to our platform and experimental products. These resources provide in-depth insights into our cutting-edge technologies and the latest developments in cancer immunotherapy.

• Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J Clin Invest. 2020
  
• Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy. Clin Transl Immunology. 2019
• Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. Immunol Cell Biol. 2017
  
• Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol. 2014
  
• Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014
  
• Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012
  

• Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial. Clin Infect Dis. 2019
• Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis. Blood Adv. 2019
• T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response. J Clin Invest. 2019
• Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation. J Heart Lung Transplant. 2016
• Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology. 2015